With the approval this month of two drugs to treat hepatitis C in children, these often overlooked victims of the opioid epidemic have a better chance at a cure.
Nearly three-quarters of HIV/hepatitis C (HCV)-coinfected drug users reported willingness to use direct-activing antivirals (DAAs) for HCV, a substantial improvement over the willingness of this group to use interferon-based regimens.
"This epidemic is even more worrying when we consider how hard it is to get treated -- only 1% of chronic carriers can access treatment."
Hepatitis C independently raised the risk of kidney disease and osteoporosis or fracture in an analysis of 5,000 people with HIV.
Wider availability of newer hepatitis C drugs may not only lead to fewer cases of this blood-borne disease, but may also slow the rise in related liver cancer.
A recent study aimed to better understand the experiences of Canadian women who receive a hepatitis C diagnosis and to provide recommendations about how to improve hepatitis C testing experiences.
Hepatitis C in Canadian Immigrants and Newcomers: Why Are Hepatitis C Rates Higher in These Populations?
Common modes of transmission, barriers related to testing and recommendations to help service providers increase access to testing and diagnosis.
Rapid point-of-care hepatitis C testing can improve both testing and linkage to care outcomes. How can this innovation impact the hepatitis C epidemic?
Can we eliminate hepatitis C the way we did to small pox? Experts think we can, and many believe we can also eradicate hepatitis B.
Hepatitis C in rectal fluid of HCV/HIV-coinfected men who have sex with men reaches levels high enough to transmit hepatitis C to insertive sex partners.